Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00639938 |
Recruitment Status
:
Completed
First Posted
: March 20, 2008
Last Update Posted
: April 2, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Nevirapine Drug: HIV immune globulin solution | Phase 3 |
There is an urgent need to find safe, effective means of preventing mother-to-child-transmission (MTCT) of HIV that can be used in developing countries. One of the greatest obstacles to prevention in these areas remains HIV transmission through breast milk. The primary purpose of this trial is to determine if nevirapine (NVP) plus immunoprophylaxis (by intravenous HIV immune globulin [HIVIGLOB]) or extended NVP dosing of the neonate during the perinatal period can safely and effectively reduce the risk of peripartum or early breastfeeding-related HIV MTCT.
This study will last 11-18 weeks for each mother and 18 months for each infant. HIV-infected pregnant women will be randomly assigned to one of three arms. Participants in Arm 1 will receive a single dose of 200 mg NVP orally at the onset of labor. Infants in Arm 1 will receive a single dose of 2 mg/kg NVP orally within the first week after delivery. Arm 2 participants will receive a single dose of 200 mg NVP orally at the onset of labor. Infants in Arm 2 will receive 2 mg/kg NVP orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6. Arm 3 participants will receive a 12 gm intravenous dose of HIVIGLOB at 36-37 weeks gestation and 200 mg NVP orally at the onset of labor. Infants in Arm 3 will receive a single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP orally within the first week after delivery.
There will be five or six study visits for pregnant participants. A targeted medical history, physical examination, and blood collection will occur at all visits. After birth, there will be 11 study visits for infants in Arms 1 and 2 and 12 study visits for infants in Arm 3. Medical history and a targeted physical exam will occur at all visits. Blood collection will occur at some visits.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 722 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Prevention |
Official Title: | A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV Transmission in Uganda |
Study Start Date : | July 2004 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | July 2007 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery |
Drug: Nevirapine
200 mg Nevirapine tablet
Other Name: NVP Viramune
|
Experimental: 2
Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6 |
Drug: Nevirapine
200 mg Nevirapine tablet
Other Name: NVP Viramune
|
Experimental: 3
Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery |
Drug: Nevirapine
200 mg Nevirapine tablet
Other Name: NVP Viramune
Drug: HIV immune globulin solution
5% intravenous HIV immune globulin solution
Other Name: HIVIGLOB
|
- Rate of HIV infection in infants born to study participants in each arm of the study [ Time Frame: At Birth, Weeks 2, 6, and 14, and Months 6, 12, and 18 ]
- Safety and tolerance of HIVIGLOB given to pregnant women at 36-37 weeks gestation and neonates at birth in combination with NVP and of NVP alone [ Time Frame: Throughout study ]
- Rate of immunologic progression in HIV-infected infants in each arm [ Time Frame: Throughout study ]
- Infant mortality [ Time Frame: Throughout study ]
- Maternal plasma HIV RNA levels at delivery [ Time Frame: At Birth ]
- Immunologic, virologic, and pharmacologic factors [ Time Frame: Throughout study ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pregnant between 32-36 weeks estimated gestation
- HIV Infected
- Intent to breastfeed infant
- Certain laboratory criteria. More information on this criterion can be found in the protocol.
Exclusion Criteria:
- Sensitivity to immune globulin preparations or any benzodiazepine
- Clinically significant disease, as determined by the investigator, that would compromise the ability of the participant to complete the study requirements
- Currently receiving antiretroviral therapy (other than the intrapartum NVP or other peripartum regimens)
- Participation in any HIV vaccine trials
- History of cytotoxic chemotherapy within one month of study entry
- Uncontrolled hypertension
- Chronic alcohol or illicit drug use
- History of non-compliance with visits or medication
- Women who become pregnant again during study follow-up will not be eligible for re-enrollment in the trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00639938
Principal Investigator: | Brooks Jackson, MD | Johns Hopkins School of Medicine |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Brooks Jackson, MD, Johns Hopkins School of Medicine |
ClinicalTrials.gov Identifier: | NCT00639938 History of Changes |
Other Study ID Numbers: |
R01AI034235 ( U.S. NIH Grant/Contract ) |
First Posted: | March 20, 2008 Key Record Dates |
Last Update Posted: | April 2, 2008 |
Last Verified: | March 2008 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Pregnancy, High-Risk HIV Seronegativity |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Nevirapine Immunoglobulins Antibodies gamma-Globulins Immunoglobulins, Intravenous |
Rho(D) Immune Globulin Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Immunologic Factors Physiological Effects of Drugs |